1. This phase 2 randomized clinical trial found that patients with metastatic colorectal cancer who were treated with cetuximab maintenance ...
1. This phase 2 randomized clinical trial found that patients with metastatic colorectal cancer who were treated with cetuximab maintenance ...
Click to read this study in JAMA Network Open.
Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. Median progression-free survival was 5.6 ...
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved ...
Click to read this study in JAMA Otolaryngology - Head & Neck Surgery.
Click to read this study in the Journal of Clinical Oncology.
Click to read this study in the European Journal of Cancer.
Click to read the study in The Lancet Oncology.
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
